Mitoxana (Ifosfamide)

Ifosfamide, the active ingredient in Mitoxana, is an alkylating agent presented as an injectable solution for intravenous use. It is employed in the treatment of several solid tumours and hematologic malignancies, particularly in adult patients with advanced disease.

GNH USA supplies Mitoxana as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with distribution aligned to EU regulatory standards. The company ensures quality control, traceability and timely delivery to meet the needs of oncology treatment programmes.

Ifosfamide is used in chemotherapy regimens targeting malignant cells in various solid tumours and lymphoid cancers. - Testicular cancer: improves remission rates in advanced disease. - Soft tissue sarcoma: reduces tumor size and prolongs progression‑free survival. - Ovarian cancer: used in combination therapy for recurrent disease. - Non‑small cell lung cancer: contributes to disease control in selected patients. - Lymphoma: incorporated in protocols for refractory or high‑risk cases.

Ifosfamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Fatigue: generalized tiredness. - Hemorrhagic cystitis: irritation of the bladder causing blood in urine. - Myelosuppression: reduced white blood cells, red cells and platelets. - Alopecia: temporary hair loss.

Serious or Rare Side Effects: - Nephrotoxicity: impaired kidney function. - Neurotoxicity: confusion, seizures or encephalopathy. - Severe infections: due to profound immunosuppression. - Cardiotoxicity: rare heart muscle damage. - Secondary malignancies: potential induction of new cancers.

When using Ifosfamide, clinicians should observe specific safety measures to minimize risks. - Hydration: ensure adequate intravenous fluids before and after infusion to reduce bladder toxicity. - Mesna co‑administration: give protective agent to prevent hemorrhagic cystitis. - Renal function monitoring: assess serum creatinine and urine output regularly. - Hematologic monitoring: perform complete blood counts to detect myelosuppression. - Pregnancy and lactation: avoid use in pregnant or nursing women unless benefits outweigh risks. - Store at ambient temperature: keep vials in original packaging, protect from light and moisture, and store below 25 °C.

Ifosfamide can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Mesna dose mismatch: insufficient mesna increases risk of bladder toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels and toxicity. - High‑dose radiation therapy: combined effect may exacerbate tissue damage.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): enhanced bleeding risk due to platelet suppression. - Other myelosuppressive agents (e.g., cyclophosphamide): additive bone‑marrow depression. - Nephrotoxic drugs (e.g., aminoglycosides): increased risk of kidney injury.